Edition:
United States

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

0.35USD
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
$0.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
95,796
52-wk High
$1.38
52-wk Low
$0.29

Latest Key Developments (Source: Significant Developments)

Eyegate Receives FDA Feedback On Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel
Monday, 9 Apr 2018 08:30am EDT 

April 9 (Reuters) - EyeGate Pharmaceuticals Inc ::EYEGATE RECEIVES FDA FEEDBACK ON INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL.IN ITS LETTER, FDA IDENTIFIED FOUR DEFICIENCIES IN COMPANY'S SUBMISSION.FDA REQUESTED ADDITIONAL INFORMATION ON MANUFACTURING PROCESSES ASSOCIATED WITH EYEGATE OBG PRODUCT.CO TARGETING SUBMISSION OF A SECOND AMENDMENT TO IDE APPLICATION IN JULY 2018.IN U.S. FDA'S LETTER, PRIMARY COMMENT RELATES TO VALIDATION OF FILTER SPECIFICALLY USED FOR STERILIZATION OF CMHA MATERIAL.  Full Article

Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln
Friday, 23 Mar 2018 05:19pm EDT 

March 23 (Reuters) - Eyegate Pharmaceuticals Inc ::EYEGATE PHARMACEUTICALS FILES FOR POTENTIAL MIXED SHELF OF UP TO $20 MILLION - SEC FILING.  Full Article

Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel
Thursday, 8 Mar 2018 08:30am EST 

March 8 (Reuters) - Eyegate Pharmaceuticals Inc ::EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL.EYEGATE PHARMACEUTICALS - SUBMITTED AMENDED IDE APPLICATION TO U.S. FDA FOR A PILOT STUDY OF EYEGATE OCULAR BANDAGE GEL.EYEGATE PHARMACEUTICALS INC - AMENDMENT SUMMARIZES CO'S RESPONSES TO FDA'S QUESTIONS AND COMMENTS IN RESPONSE TO ORIGINAL IDE SUBMISSION.EYEGATE PHARMACEUTICALS INC - AMENDMENT INCLUDES VALIDATION DATA ON MANUFACTURING PROCESSES AND BIOBURDEN TESTS RELATED TO PRODUCTION OF EYEGATE OBG.EYEGATE PHARMACEUTICALS INC - CONTINUE TO MOVE FORWARD TOWARD PLANNED 510(K) DE NOVO FILING IN 2019 FOR EYEGATE OBG.  Full Article

Eyegate Promotes Sarah Romano To CFO
Thursday, 4 Jan 2018 08:30am EST 

Jan 4 (Reuters) - Eyegate Pharmaceuticals Inc ::EYEGATE PROMOTES SARAH ROMANO TO CHIEF FINANCIAL OFFICER.EYEGATE PHARMACEUTICALS-ANNOUNCED PROMOTION OF SARAH ROMANO FROM INTERIM CFO TO CFO, EFFECTIVE JANUARY 1, 2018.  Full Article

EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment
Monday, 18 Dec 2017 08:30am EST 

Dec 18 (Reuters) - EyeGate Pharmaceuticals Inc ::EYEGATE ACHIEVES 75% ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL FOR ANTERIOR UVEITIS TRIGGERING MILESTONE PAYMENT.EYEGATE PHARMACEUTICALS INC - TOPLINE DATA IS EXPECTED TO BE RELEASED IN Q2 OF 2018..EYEGATE PHARMA - REMAIN ON-TRACK TO REPORT TOPLINE DATA FROM TRIAL IN Q2 2018, WITH EXPECTED NDA FILING FOR EGP-437 IN ANTERIOR UVEITIS NEXT YEAR.  Full Article

Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago
Tuesday, 14 Nov 2017 08:00am EST 

Nov 14 (Reuters) - Eyegate Pharmaceuticals Inc :Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update.Eyegate Pharmaceuticals Inc - ‍net loss in Q3 of 2017 was $4.1 million, compared with $3.4 million in Q3 of 2016​.  Full Article

EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery
Wednesday, 8 Nov 2017 08:30am EST 

Nov 8 (Reuters) - EyeGate Pharmaceuticals Inc :EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery.Eyegate Pharmaceuticals Inc - ‍topline data is expected to be released in Q1 of 2018 for phase 2b clinical trial of EGP-437 for cataract surgery​.  Full Article

Eyegate Pharmaceuticals Q2 revenue $148,000
Monday, 7 Aug 2017 07:30am EDT 

Aug 7 (Reuters) - Eyegate Pharmaceuticals Inc :Eyegate Pharmaceuticals reports second quarter 2017 financial results and provides business update.Q2 revenue $148,000 versus $235,000.Q2 revenue view $1.5 million -- Thomson Reuters I/B/E/S.Eyegate Pharmaceuticals Inc - ‍net loss for Q2 of 2017 was $3.3 million, compared with $3.8 million in Q2 of 2016​.Eyegate Pharmaceuticals Inc - cash and cash equivalents as of June 30, 2017 totaled $11.8 million, compared with $3.6 million as of December 31, 2016.  Full Article

Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc
Monday, 19 Jun 2017 05:10pm EDT 

June 19 (Reuters) - Armistice Capital LLC : :Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc, as of June 9, 2017 .  Full Article

Innoven Partenaires reports a 9.5 pct stake in Eyegate Pharmaceuticals
Friday, 16 Jun 2017 07:19am EDT 

June 16 (Reuters) - Innoven Partenaires S.A.::Innoven Partenaires S.A. reports a 9.5 percent stake in Eyegate Pharmaceuticals Inc as of June 14 - SEC filing.Innoven Partenaires S.A. had previously reported a 24.2 percent stake in Eyegate Pharmaceuticals Inc as of Feb 19, 2015.  Full Article

BRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel

* EYEGATE ADDRESSES MAJORITY OF FDA’S ACTION ITEMS WITH SUBMISSION OF INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR OCULAR BANDAGE GEL